Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.14.5599

Hybrid Imaging in Oncology  

Fatima, Nosheen (Department of Nuclear Medicine, Dr. Ziauddin Medical University)
uz Zaman, Maseeh (Section of Nuclear Medicine, Department of Radiology, Aga Khan University Hospital (AKUH))
Gnanasegaran, Gopinath (Department of Molecular Imaging, Guy's & St Thomas' NHS Trust)
Zaman, Unaiza (Dow University of Health Sciences (DUHS))
Shahid, Wajeeha (Dow University of Health Sciences (DUHS))
Zaman, Areeba (Dow University of Health Sciences (DUHS))
Tahseen, Rabia (Dow University of Health Sciences (DUHS))
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.14, 2015 , pp. 5599-5605 More about this Journal
Abstract
In oncology various imaging modalities play a crucial role in diagnosis, staging, restaging, treatment monitoring and follow up of various cancers. Stand-alone morphological imaging like computerized tomography (CT) and magnetic resonance imaging (MRI) provide a high magnitude of anatomical details about the tumor but are relatively dumb about tumor physiology. Stand-alone functional imaging like positron emission tomography (PET) and single photon emission tomography (SPECT) are rich in functional information but provide little insight into tumor morphology. Introduction of first hybrid modality PET/CT is the one of the most successful stories of current century which has revolutionized patient care in oncology due to its high diagnostic accuracy. Spurred on by this success, more hybrid imaging modalities like SPECT/CT and PET/MR were introduced. It is the time to explore the potential applications of the existing hybrid modalities, developing and implementing standardized imaging protocols and train users in nuclear medicine and radiology. In this review we discuss three existing hybrid modalities with emphasis on their technical aspects and clinical applications in oncology.
Keywords
Hybrid imaging; PET/CT; PET/MR; PET/SPECT; anatomometabolic aspects;
Citations & Related Records
Times Cited By KSCI : 3  (Citation Analysis)
연도 인용수 순위
1 Aspinall MG, Hamermesh RG (2007). Realizing the promise of personalized medicine. Harv Bus Rev, 85,117-65.
2 Amoui M, Akbari ME, Tajeddini A, et al (2012). Value of sentinel lymph node biopsy in breast cancer surgery with simple pathology facilities-An Iranian local experience with a review of potential causes of false negative results. Asian Pac J Cancer Prev, 13, 5385-89.   DOI
3 Avram AM (2012). Radioiodine scintigraphy with SPECT/CT: an important diagnostic tool for thyroid cancer staging and risk stratification. J Nucl Med, 53, 754-64.
4 Blankespoor SC, Wu X, Kalki JK (1996). Attenuation correction of SPECT using X-ray CT on an emission-transmission CT system: myocardial perfusion assessment. IEEE Trans Nucl Sci, 43, 2263-74.   DOI
5 Buck A, Nekolla S, Ziegler S, et al (2008). SPECT/CT. J Nucl Med, 49, 1305-19.   DOI
6 Bockisch Am, Freudenberg LS, Schmidt D, Kuwert T (2008). Hybrid imaging by SPECT/CT and PET/CT: proven outcomes in cancer imaging. Semin Nucl Med, 39, 276-89.
7 Ben-Haim S, Ell P (2009). 18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response. J Nucl Med, 50, 88-99.
8 Beyer T, Freudenberg LS, Townsend DW, Czernin J (2011). The future of hybrid imaging-part 1: hybrid imaging technologies and SPECT/CT. Insights Imaging, 2, 161-69.   DOI
9 Beyer T, Townsend DW, Czernin J, Freudenberg LS (2011). The future of hybrid imaging-part 2: PET/CT. Insights Imaging, 2, 225-34.   DOI
10 Castellino RA, Hilton S, O'Brien P, et al (1996). Non-Hodgkin lymphoma: contribution of chest CT in the initial staging solution. Radiology, 199, 129-32.   DOI
11 Czernin J, Allen-Auerbach M, Schelbert H (2007). Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med, 48, 78-88.
12 Delso G, Furst S, Jakoby B, et al (2011). Performance measurements of the siemens mMR integrated whole-body PET/MR scanner. J Nucl Med, 52, 1-9.   DOI
13 Even-Sapir E, Lerman H, Lievshitz G, et al (2003). Lymphoscintigraphy for sentinel node mapping using a hybrid SPECT/CT system. J Nucl Med, 44, 1413-20.
14 Fontaine R, Belanger F, Viscogliosi N, et al (2009). "The hardware and signal processing architecture of LabPETTM, a small animal APD-based digital PET scanner. IEEE Trans Nucl Sci, 56, 3-9.   DOI
15 Flohr TG, Ernst K, Thomas A, et al (2010). Pushing the envelope: new computed tomography techniques for cardiothoracic imaging. J Thorac Imaging, 25, 100-11.   DOI
16 Hutton BF, Braun M, Thurfjell L, Lau DYH (2002). Image registration: an essential tool for nuclear medicine. Eur J Nucl Med Mol Imaging, 29, 559-77.   DOI
17 Inaoka T, Takahashi K, Mineta M, et al (2007). Thymic hyperplasia and thymus gland tumors: differentiation with chemical shift MR imaging. Radiology, 243, 869-76.   DOI
18 Jaszczak RJ, Coleman RE, Lim CB (1980). SPECT: Single photon emission computed tomography. IEEE Tran Nucl Sci, 27, 1137-53.   DOI
19 Keidar Z, Israel O, Krausz Y (2003). SPECT/CT in tumor imaging: technical aspects and clinical applications. Semin Nucl Med, 33, 205-18.   DOI
20 Kaya AO, Coskun U, Unlu M, et al (2008). Whole body 18FDG PET/CT imaging in the detection of primary tumors in patients with a metastatic carcinoma of unknown origin. Asian Pac J Cancer Prev, 9, 683-86.
21 Lerman H, Metser U, Lievshitz G, et al (2006). Lymphoscintigraphic sentinel node identi?cation in patients with breast cancer: the roll of SPECT-CT. Eur J Nucl Med Mol Imaging, 33, 329-37.
22 Mian C, Barollo S, Pennelli G, et al (2008). Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf), 68, 108-16.   DOI
23 Lerman H, Lievshitz G, Zak O, et al (2007). Even-Sapir E. improved sentinel node identification by SPECT/CT in Overweight Patients with Breast Cancer. J Nucl Med, 48, 201-06.
24 Liu J, Yang X, Li F, Wang X, Jiang X (2011). Preliminary study of whole-body diffusion-weighted imaging in detecting pulmonary metastatic lesions from clear cell renal cell carcinoma: comparison with CT. Acta Radiol, 52, 954-63.   DOI
25 Liu NB, Zhu L, Li MH, Sun XR, et al (2013). Diagnostic value of 18F-FDG PET/CT in comparison to bone scintigraphy, CT and 18F-FDG PET for the detection of bone Metastasis. Asian Pac J Cancer Prev, 14, 3647-52.   DOI   ScienceOn
26 Moy L, Noz ME, Maguire GQ et al (2010). Role of fusion of prone FDG-PET and magnetic resonance imaging of the breasts in the evaluation of breast cancer. Breast J, 16, 369-76.
27 Mainenti PP, Iodice D, Segreto S, et al (2011). Colorectal cancer and $^{18}$FDG-PET/CT: what about adding the T to the N parameter in loco-regional staging? World J Gastroenterol, 17, 1427-33.   DOI
28 Mansi L, Ciarmiello A, Cuccurullo V (2012). PET/MRI and the revolution of the third eye. Eur J Nucl Med Mol Imaging, 39, 1519-24.   DOI
29 Papathanassiou D, Liehn JC (2008). The growing development of multimodality imaging in oncology. Critical Rev Oncol Hematol, 68, 60-5.   DOI
30 Petronis JD, Regan F, Lin K (1998). Indium-111 capromab pendetide (prostascint) imaging to detect recurrent and metastatic prostate cancer. Clin Nucl Med, 23, 672-77.   DOI
31 Rufini V, Calcagni ML, Baum RP (2006). Imaging of neuroendocrine tumors. Semin Nucl Med, 36, 228-47.   DOI
32 Park JW, Kim JH, Kim SK, et al (2008). Choi JI, Lee WJ, Kim CM, Nam BH. a prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med, 49, 1912-21.   DOI
33 Pichler BJ, Kolb A, Nagele T, Schlemmer HP (2010). PET/MRI: Paving the Way for the Next Generation of Clinical Multimodality Imaging Applications. J Nucl Med, 51, 333-36.   DOI
34 Pace L, Nicolai E, Aiello M, Catalano OA, Salvatore M (2013). Whole-body PET/MRI in oncology: current status and clinical Applications. Clin Transl Imaging, 1, 31-44.   DOI
35 Sodee DB, Sodee AE, Bakale G (2007). Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med, 37, 17-28.   DOI
36 Strauss LG, Conti PS (1991). The application of PET in clinical oncology. J Nucl Med, 32, 623-48.
37 Shao Y, Cherry SR, Farahani K, et al (1997). Simultaneous PET and MR imaging. Phys Med Biol, 42, 1965-70.   DOI
38 Schmidt GP, Schoenberg SO, Schmid R, et al (2007). Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol, 17, 939-49.   DOI
39 Townsend D (2008). Multimodality imaging of structure and function. Phys Med Biol, 53, R1-R39   DOI
40 Tateishi U, Hosono A, Makimoto A, et al (2009). Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. Ann Nucl Med, 23, 155-61.   DOI
41 Wahl RL, Quint LE, Cieslak RD, al (1993). "Anatometabolic" tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity. J Nucl Med, 34, 1190-97.
42 Thamnirat K, Utamakul C, Chamroonrat V, et al (2015). Factors affecting disease-free status of differentiated thyroid carcinoma patients. Asian Pac J Cancer Prev, 16, 737-40.   DOI
43 Vandecaveye V, De Keyzer F, Vander PV, et al (2009). Head and neck squamous cell carcinoma: value of diffusion-weighted MR imaging for nodal staging. Radiology, 251, 134-46.   DOI
44 Watson CC, Casey ME, Bendriem B, et al (2005). Optimizing injected dose in clinical PET by accurately modeling the counting-rate response functions specific to individual patient scans. J Nucl Med, 46, 1825-34.
45 Wagner HN. (2005). A personal history of nuclear medicine. Springer, London .
46 www-pub.iaea.org/MTCD/publications/PDF/te_1597_web.pdf. (visited 20.2.2014).
47 Zaman M, Fatima N, Sajjad Z, Zaman Unaiza (2014). Whole body simultaneous PET/MRI: One-stop-shop? JPMA, 64, 201-05.